Allograft inflammatory factor-1 supports macrophage survival and efferocytosis and limits necrosis in atherosclerotic plaques

Lander Egaña-Gorroño, Prameladevi Chinnasamy, Isabel Casimiro, Vanessa M. Almonte, Dippal Parikh, Gustavo H. Oliveira-Paula, Smitha Jayakumar, Calvin Law, Dario F. Riascos-Bernal, Nicholas E.S. Sibinga

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background and aims: Allograft inflammatory factor-1 (AIF1) has been characterized as a pro-inflammatory molecule expressed primarily in the monocyte/macrophage (MP) lineage and positively associated with various forms of vascular disease, including atherosclerosis. Studies of AIF1 in atherosclerosis have relied on mouse models in which AIF1 was overexpressed in either myeloid or smooth muscle cells, resulting in increased atherosclerotic plaque burden. How physiologic expression of AIF1 contributes to MP biology in atherogenesis is not known. Methods: Effects of global AIF1 deficiency on atherosclerosis were assessed by crossing Aif1−/− and ApoE−/− mice, and provoking hyperlipidemia with high fat diet feeding. Atherosclerotic plaques were studied en face and in cross section. Bone marrow-derived MPs (BMDMs) were isolated from Aif1−/− mice for study in culture. Results: Atherosclerotic plaques in Aif1−/−;ApoE−/− mice showed larger necrotic cores compared to those in ApoE−/− animals, without change in overall lesion burden. In vitro, lack of AIF1 reduced BMDM survival, phagocytosis, and efferocytosis. Mechanistically, AIF1 supported activation of the NF-κB pathway and expression of related target genes involved in stress response, inflammation, and apoptosis. Consistent with this in vitro BMDM phenotype, AIF1 deficiency reduced NF-κB pathway activity in vivo and increased apoptotic cell number in atherosclerotic lesions from Aif1−/−;ApoE−/− mice. Conclusions: These findings characterize AIF1 as a positive regulator of the NF-κB pathway that supports MP functions such as survival and efferocytosis. In inflammatory settings such as atherosclerosis, these AIF1-dependent activities serve to clear cellular and other debris and limit necrotic core expansion, and may oppose lesion destabilization.

Original languageEnglish (US)
JournalAtherosclerosis
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Atherosclerotic Plaques
Allografts
Necrosis
Macrophages
Apolipoproteins E
Atherosclerosis
Bone Marrow
High Fat Diet
Hyperlipidemias
Vascular Diseases
Phagocytosis
Smooth Muscle Myocytes
Monocytes
Cell Count
Apoptosis
Inflammation
Phenotype

Keywords

  • Atherosclerosis
  • Efferocytosis
  • Macrophage
  • Necrosis
  • NF-κB

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Allograft inflammatory factor-1 supports macrophage survival and efferocytosis and limits necrosis in atherosclerotic plaques. / Egaña-Gorroño, Lander; Chinnasamy, Prameladevi; Casimiro, Isabel; Almonte, Vanessa M.; Parikh, Dippal; Oliveira-Paula, Gustavo H.; Jayakumar, Smitha; Law, Calvin; Riascos-Bernal, Dario F.; Sibinga, Nicholas E.S.

In: Atherosclerosis, 01.01.2019.

Research output: Contribution to journalArticle

Egaña-Gorroño, L, Chinnasamy, P, Casimiro, I, Almonte, VM, Parikh, D, Oliveira-Paula, GH, Jayakumar, S, Law, C, Riascos-Bernal, DF & Sibinga, NES 2019, 'Allograft inflammatory factor-1 supports macrophage survival and efferocytosis and limits necrosis in atherosclerotic plaques', Atherosclerosis. https://doi.org/10.1016/j.atherosclerosis.2019.07.022
Egaña-Gorroño, Lander ; Chinnasamy, Prameladevi ; Casimiro, Isabel ; Almonte, Vanessa M. ; Parikh, Dippal ; Oliveira-Paula, Gustavo H. ; Jayakumar, Smitha ; Law, Calvin ; Riascos-Bernal, Dario F. ; Sibinga, Nicholas E.S. / Allograft inflammatory factor-1 supports macrophage survival and efferocytosis and limits necrosis in atherosclerotic plaques. In: Atherosclerosis. 2019.
@article{c70b556784ca4d5791823ee0740a5c5f,
title = "Allograft inflammatory factor-1 supports macrophage survival and efferocytosis and limits necrosis in atherosclerotic plaques",
abstract = "Background and aims: Allograft inflammatory factor-1 (AIF1) has been characterized as a pro-inflammatory molecule expressed primarily in the monocyte/macrophage (MP) lineage and positively associated with various forms of vascular disease, including atherosclerosis. Studies of AIF1 in atherosclerosis have relied on mouse models in which AIF1 was overexpressed in either myeloid or smooth muscle cells, resulting in increased atherosclerotic plaque burden. How physiologic expression of AIF1 contributes to MP biology in atherogenesis is not known. Methods: Effects of global AIF1 deficiency on atherosclerosis were assessed by crossing Aif1−/− and ApoE−/− mice, and provoking hyperlipidemia with high fat diet feeding. Atherosclerotic plaques were studied en face and in cross section. Bone marrow-derived MPs (BMDMs) were isolated from Aif1−/− mice for study in culture. Results: Atherosclerotic plaques in Aif1−/−;ApoE−/− mice showed larger necrotic cores compared to those in ApoE−/− animals, without change in overall lesion burden. In vitro, lack of AIF1 reduced BMDM survival, phagocytosis, and efferocytosis. Mechanistically, AIF1 supported activation of the NF-κB pathway and expression of related target genes involved in stress response, inflammation, and apoptosis. Consistent with this in vitro BMDM phenotype, AIF1 deficiency reduced NF-κB pathway activity in vivo and increased apoptotic cell number in atherosclerotic lesions from Aif1−/−;ApoE−/− mice. Conclusions: These findings characterize AIF1 as a positive regulator of the NF-κB pathway that supports MP functions such as survival and efferocytosis. In inflammatory settings such as atherosclerosis, these AIF1-dependent activities serve to clear cellular and other debris and limit necrotic core expansion, and may oppose lesion destabilization.",
keywords = "Atherosclerosis, Efferocytosis, Macrophage, Necrosis, NF-κB",
author = "Lander Ega{\~n}a-Gorro{\~n}o and Prameladevi Chinnasamy and Isabel Casimiro and Almonte, {Vanessa M.} and Dippal Parikh and Oliveira-Paula, {Gustavo H.} and Smitha Jayakumar and Calvin Law and Riascos-Bernal, {Dario F.} and Sibinga, {Nicholas E.S.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.atherosclerosis.2019.07.022",
language = "English (US)",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Allograft inflammatory factor-1 supports macrophage survival and efferocytosis and limits necrosis in atherosclerotic plaques

AU - Egaña-Gorroño, Lander

AU - Chinnasamy, Prameladevi

AU - Casimiro, Isabel

AU - Almonte, Vanessa M.

AU - Parikh, Dippal

AU - Oliveira-Paula, Gustavo H.

AU - Jayakumar, Smitha

AU - Law, Calvin

AU - Riascos-Bernal, Dario F.

AU - Sibinga, Nicholas E.S.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background and aims: Allograft inflammatory factor-1 (AIF1) has been characterized as a pro-inflammatory molecule expressed primarily in the monocyte/macrophage (MP) lineage and positively associated with various forms of vascular disease, including atherosclerosis. Studies of AIF1 in atherosclerosis have relied on mouse models in which AIF1 was overexpressed in either myeloid or smooth muscle cells, resulting in increased atherosclerotic plaque burden. How physiologic expression of AIF1 contributes to MP biology in atherogenesis is not known. Methods: Effects of global AIF1 deficiency on atherosclerosis were assessed by crossing Aif1−/− and ApoE−/− mice, and provoking hyperlipidemia with high fat diet feeding. Atherosclerotic plaques were studied en face and in cross section. Bone marrow-derived MPs (BMDMs) were isolated from Aif1−/− mice for study in culture. Results: Atherosclerotic plaques in Aif1−/−;ApoE−/− mice showed larger necrotic cores compared to those in ApoE−/− animals, without change in overall lesion burden. In vitro, lack of AIF1 reduced BMDM survival, phagocytosis, and efferocytosis. Mechanistically, AIF1 supported activation of the NF-κB pathway and expression of related target genes involved in stress response, inflammation, and apoptosis. Consistent with this in vitro BMDM phenotype, AIF1 deficiency reduced NF-κB pathway activity in vivo and increased apoptotic cell number in atherosclerotic lesions from Aif1−/−;ApoE−/− mice. Conclusions: These findings characterize AIF1 as a positive regulator of the NF-κB pathway that supports MP functions such as survival and efferocytosis. In inflammatory settings such as atherosclerosis, these AIF1-dependent activities serve to clear cellular and other debris and limit necrotic core expansion, and may oppose lesion destabilization.

AB - Background and aims: Allograft inflammatory factor-1 (AIF1) has been characterized as a pro-inflammatory molecule expressed primarily in the monocyte/macrophage (MP) lineage and positively associated with various forms of vascular disease, including atherosclerosis. Studies of AIF1 in atherosclerosis have relied on mouse models in which AIF1 was overexpressed in either myeloid or smooth muscle cells, resulting in increased atherosclerotic plaque burden. How physiologic expression of AIF1 contributes to MP biology in atherogenesis is not known. Methods: Effects of global AIF1 deficiency on atherosclerosis were assessed by crossing Aif1−/− and ApoE−/− mice, and provoking hyperlipidemia with high fat diet feeding. Atherosclerotic plaques were studied en face and in cross section. Bone marrow-derived MPs (BMDMs) were isolated from Aif1−/− mice for study in culture. Results: Atherosclerotic plaques in Aif1−/−;ApoE−/− mice showed larger necrotic cores compared to those in ApoE−/− animals, without change in overall lesion burden. In vitro, lack of AIF1 reduced BMDM survival, phagocytosis, and efferocytosis. Mechanistically, AIF1 supported activation of the NF-κB pathway and expression of related target genes involved in stress response, inflammation, and apoptosis. Consistent with this in vitro BMDM phenotype, AIF1 deficiency reduced NF-κB pathway activity in vivo and increased apoptotic cell number in atherosclerotic lesions from Aif1−/−;ApoE−/− mice. Conclusions: These findings characterize AIF1 as a positive regulator of the NF-κB pathway that supports MP functions such as survival and efferocytosis. In inflammatory settings such as atherosclerosis, these AIF1-dependent activities serve to clear cellular and other debris and limit necrotic core expansion, and may oppose lesion destabilization.

KW - Atherosclerosis

KW - Efferocytosis

KW - Macrophage

KW - Necrosis

KW - NF-κB

UR - http://www.scopus.com/inward/record.url?scp=85070666824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070666824&partnerID=8YFLogxK

U2 - 10.1016/j.atherosclerosis.2019.07.022

DO - 10.1016/j.atherosclerosis.2019.07.022

M3 - Article

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

ER -